Retrospective B-STYPE
cohort I-STYPE
study E-STYPE
of O
trifluridine/ B-DESC
tipiracil I-DESC
( I-DESC
TAS-102 I-DESC
) E-DESC
plus B-DESC
bevacizumab E-DESC
versus O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
for O
metastatic O
colorectal O
cancer O
Retrospective B-STYPE
cohort I-STYPE
study E-STYPE
of O
trifluridine/ O
tipiracil O
( O
TAS-102 O
) O
plus O
bevacizumab O
versus O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
for O
metastatic O
colorectal O
cancer O
DaisukeKotani S-AUTH
 
Japan O
Kashiwa O
Japan O
Retrospective B-STYPE
cohort I-STYPE
study E-STYPE
of O
trifluridine/ B-DESC
tipiracil I-DESC
( I-DESC
TAS-102 I-DESC
) E-DESC
plus B-DESC
bevacizumab E-DESC
versus O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
for O
metastatic O
colorectal O
cancer O
10.1186 O
/ O
s12885 O
- O
019 O
- O
6475 O
- O
6 O
Received O
: O
24 O
August O
2019 O
Accepted O
: O
17 O
December O
2019 O
 
Colorectal O
cancer O
( O
CRC O
) O
is O
the O
second O
leading O
cause O
of O
cancer O
- O
related O
death O
worldwide O
[ O
1 O
] O
. O
The O
development O
of O
combination O
chemotherapy O
regimens O
comprising O
cytotoxic O
agents O
( O
e.g. O
, O
fluoropyrimidine O
, O
oxaliplatin O
, O
and O
irinotecan O
) O
and O
molecular O
targeted O
therapies O
( O
e.g. O
, O
bevacizumab O
, O
ramucirumab O
, O
ziv O
- O
aflibercept O
, O
cetuximab O
, O
panitumumab O
, O
and O
regorafenib O
) O
have O
increased O
the O
survival O
of O
patients O
with O
metastatic O
CRC O
( O
mCRC O
) O
by O
approximately O
30 O
months O
[ O
2][3][4][5][6][7 O
] O
. O
 
Trifluridine O
/ O
tipiracil O
( O
TAS-102 O
) O
is O
a O
novel O
, O
oral O
combination O
comprising O
the O
thymidine O
- O
based O
nucleoside O
analog O
trifluridine O
and O
tipiracil O
hydrochloride O
at O
a O
molar O
ratio O
of O
1:0.5 O
. O
Trifluridine O
is O
incorporated O
into O
DNA O
after O
phosphorylation O
by O
thymidine O
kinase O
1 O
( O
TK1 O
) O
. O
We O
previously O
reported O
results O
from O
a O
randomized O
phase O
2 O
study O
of O
trifluridine O
/ O
tipiracil O
( O
J003 O
- O
10040030 O
) O
, O
and O
this O
therapy O
was O
first O
approved O
in O
Japan O
in O
2014 O
[ O
8 O
] O
. O
More O
recently O
, O
the O
international O
phase O
3 O
RECOURSE O
trial O
has O
demonstrated O
a O
more O
significant O
overall O
survival O
( O
OS O
) O
benefit O
of O
trifluridine/ O
tipiracil O
compared O
with O
placebo O
, O
with O
acceptable O
toxicity O
, O
in O
patients O
with O
refractory O
mCRC O
[ O
7 O
] O
. O
In O
addition O
, O
the O
Asian O
phase O
3 O
TERRA O
trial O
has O
reported O
the O
survival O
benefit O
and O
safety O
of O
trifluridine O
/ O
tipiracil O
in O
Asian O
population O
[ O
9 O
] O
. O
Based O
on O
these O
findings O
, O
trifluridine O
/ O
tipiracil O
has O
been O
approved O
by O
many O
countries O
and O
regions O
including O
the O
US O
Food O
and O
Drug O
Administration O
and O
European O
Medicines O
Agency O
. O
 
The O
combination O
of O
trifluridine O
/ O
tipiracil O
plus O
bevacizumab O
has O
been O
demonstrated O
to O
have O
synergistic O
activity O
in O
a O
xenograft O
model O
of O
human O
CRC O
[ O
10 O
] O
. O
We O
have O
reported O
results O
from O
the O
phase O
1/2 O
C O
- O
TASK O
FORCE O
showing O
a O
promising O
activity O
of O
the O
aforementioned O
combination O
in O
patients O
with O
pretreated O
mCRC O
. O
The O
primary O
endpoint O
of O
16-week O
progression O
- O
free O
survival O
( O
PFS O
) O
was O
42.9 O
% O
[ O
80 O
% O
confidence O
interval O
( O
CI O
) O
, O
27.8 O
- O
59.0 O
] O
. O
The O
most O
common O
grade O
â‰¥ O
3 O
adverse O
events O
were O
neutropenia O
( O
72 O
% O
) O
, O
leucopenia O
( O
44 O
% O
) O
, O
anemia O
( O
16 O
% O
) O
, O
febrile O
neutropenia O
( O
16 O
% O
) O
, O
and O
thrombocytopenia O
( O
12 O
% O
) O
[ O
11 O
] O
. O
Managing O
the O
higher O
incidence O
of O
hematological O
toxicities O
is O
crucial O
to O
reduce O
the O
risks O
of O
serious O
treatment O
- O
related O
adverse O
events O
and O
maximize O
the O
efficacy O
of O
trifluridine O
/ O
tipiracil O
plus O
bevacizumab O
treatment O
. O
Furthermore O
, O
the O
non O
- O
comparative O
phase O
2 O
TASCO1 O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
trifluridine O
/ O
tipiracil O
plus O
bevacizumab O
and O
capecitabine O
plus O
bevacizumab O
and O
provided O
evidence O
demonstrating O
the O
efficacy O
of O
trifluridine O
/ O
tipiracil O
plus O
bevacizumab O
in O
patients O
with O
untreated O
mCRC O
who O
were O
not O
eligible O
for O
standard O
first O
- O
line O
intensive O
therapy O
. O
The O
primary O
endpoint O
of O
PFS O
was O
9.2 O
months O
in O
the O
trifluridine O
/ O
tipiracil O
plus O
bevacizumab O
group O
and O
7.8 O
months O
in O
the O
capecitabine O
plus O
bevacizumab O
group O
[ O
12 O
] O
. O
 
Although O
trifluridine O
/ O
tipiracil O
plus O
bevacizumab O
is O
a O
promising O
regimen O
for O
mCRC O
patients O
, O
little O
is O
known O
about O
the O
survival O
benefit O
and O
safety O
profile O
of O
the O
combination O
compared O
with O
trifluridine O
/ O
tipiracil O
monotherapy O
. O
Therefore O
, O
the O
aim O
of O
this O
study O
was O
to O
investigate O
efficacy O
and O
safety O
of O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
compared O
with O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
in O
the O
clinical O
practice O
. O
 
Clinical O
data O
of O
patients O
with O
mCRC O
who O
received O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
or O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
at O
the O
National O
Cancer O
Center O
Hospital O
East O
was O
retrospectively B-STYPE
collected E-STYPE
. O
Study O
protocol O
was O
approved O
by O
the O
institutional O
review O
board O
. O
Informed O
consent O
requirement O
was O
waived O
due O
to O
the O
study B-STYPE
's I-STYPE
observational I-STYPE
retrospective I-STYPE
design E-STYPE
, O
with O
an O
opt O
- O
out O
opportunity O
provided O
at O
the O
institution O
's O
website O
. O
Patient O
follow O
- O
up O
was O
performed O
until O
December O
2018 O
. O
 
Eligibility O
criteria O
were O
as O
follows O
: O
histologically O
confirmed O
colorectal O
adenocarcinoma O
; O
no O
prior O
treatment O
with O
regorafenib O
; O
refractory O
or O
intolerant O
to O
fluoropyrimidine O
, O
oxaliplatin O
, O
and O
irinotecan O
, O
regardless O
of O
angiogenesis O
inhibitors O
or O
anti O
- O
EGFR O
antibody O
( O
if O
RAS O
wildtype O
) O
; O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
( O
ECOG O
PS O
) O
0 O
to O
2 O
; O
adequate O
organ O
function O
; O
concurrent O
treatment O
with O
trifluridine O
/ O
tipiracil O
plus O
bevacizumab O
from O
January O
2016 O
to O
March O
2018 O
or O
trifluridine O
/ O
tipiracil O
monotherapy O
from O
June O
2014 O
to O
December O
2015 O
. O
 
Trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus O
bevacizumab O
regimen O
consisted O
of O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
35 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
of I-DOSAGE
body I-DOSAGE
surface I-DOSAGE
area I-DOSAGE
, I-DOSAGE
given I-DOSAGE
orally I-DOSAGE
twice I-DOSAGE
a I-DOSAGE
day I-DOSAGE
on I-DOSAGE
days I-DOSAGE
1 I-DOSAGE
- I-DOSAGE
5 I-DOSAGE
and I-DOSAGE
8 I-DOSAGE
- I-DOSAGE
12 I-DOSAGE
in I-DOSAGE
a I-DOSAGE
28-day I-DOSAGE
cycle E-DOSAGE
, O
and O
bevacizumab S-DESC
5 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
kg I-DOSAGE
of I-DOSAGE
bodyweight I-DOSAGE
, I-DOSAGE
administered I-DOSAGE
by I-DOSAGE
intravenous I-DOSAGE
infusion I-DOSAGE
every I-DOSAGE
2 I-DOSAGE
weeks E-DOSAGE
. O
Trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
consisted O
of O
trifluridine/ B-DESC
tipiracil E-DESC
35 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
of I-DOSAGE
body I-DOSAGE
surface I-DOSAGE
area I-DOSAGE
, I-DOSAGE
given I-DOSAGE
orally I-DOSAGE
twice I-DOSAGE
a I-DOSAGE
day I-DOSAGE
on I-DOSAGE
days I-DOSAGE
1 I-DOSAGE
- I-DOSAGE
5 I-DOSAGE
and I-DOSAGE
8 I-DOSAGE
- I-DOSAGE
12 I-DOSAGE
in I-DOSAGE
a I-DOSAGE
28-day I-DOSAGE
cycle E-DOSAGE
. O
 
The O
following O
baseline O
characteristics O
were O
collected O
for O
each O
patient O
: O
age O
, O
gender O
, O
ECOG O
PS O
, O
primary O
tumor O
location O
, O
history O
of O
primary O
resection O
, O
number O
of O
metastatic O
organs O
, O
time O
from O
first O
- O
line O
chemotherapy O
start O
, O
time O
from O
prior O
bevacizumab O
, O
prior O
chemotherapy O
agents O
, O
RAS O
status O
( O
KRAS O
exons O
2 O
, O
3 O
, O
and O
4 O
and O
NRAS O
exons O
2 O
, O
3 O
, O
and O
4 O
) O
, O
BRAF O
V600E O
mutation O
status O
, O
and O
microsatellite O
instability O
( O
MSI O
) O
status O
, O
if O
available O
. O
 
Efficacy O
endpoints O
included O
PFS S-METRIC
, O
defined O
as O
time O
from O
study O
treatment O
initiation O
to O
disease O
progression O
or O
death O
due O
to O
any O
cause O
; O
OS O
, O
defined O
as O
time O
from O
study O
treatment O
start O
to O
death O
from O
any O
cause O
; O
overall O
response O
rate O
( O
ORR O
) O
, O
defined O
as O
proportion O
of O
patients O
with O
a O
complete O
or O
partial O
response O
to O
study O
treatment O
; O
disease O
control O
rate O
( O
DCR O
) O
, O
defined O
as O
proportion O
of O
patients O
with O
a O
complete O
or O
partial O
response O
plus O
stable O
disease O
lasting O
more O
than O
6 O
weeks O
from O
study O
treatment O
start O
. O
Tumor O
response O
was O
assessed O
by O
investigators O
using O
the O
Response O
Evaluation O
Criteria O
in O
Solid O
Tumors O
version O
1.1 O
. O
Adverse O
events O
were O
evaluated O
using O
the O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
version O
4.03 O
. O
 
PFS S-METRIC
and O
OS O
were O
compared O
between O
treatment O
groups O
using O
log O
- O
rank O
test O
with O
a O
two O
- O
sided O
significance O
level O
of O
p O
= O
0.05 O
. O
Hazard O
ratio O
( O
HR O
) O
and O
corresponding O
95 O
% O
CI O
were O
determined O
using O
a O
Cox O
proportional O
hazard O
model O
. O
Survival O
curves O
were O
generated O
using O
Kaplan O
- O
Meier O
estimates O
. O
Univariate O
and O
multivariate O
analyses O
were O
performed O
to O
evaluate O
the O
impact O
of O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
or O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
treatments O
. O
Regression O
analysis O
covariates O
included O
treatment O
group O
, O
age O
, O
gender O
, O
ECOG O
PS O
, O
primary O
tumor O
location O
, O
RAS O
status O
, O
time O
from O
first O
- O
line O
chemotherapy O
start O
, O
and O
time O
from O
prior O
bevacizumab O
. O
Multivariate O
Cox O
analysis O
was O
employed O
using O
forward O
stepwise O
regression O
. O
Enter O
and O
remove O
limits O
were O
p O
= O
0.05 O
and O
p O
= O
0.20 O
, O
respectively O
. O
Confounding O
variables O
considered O
in O
multivariate O
analysis O
included O
age O
( O
< O
65 O
years O
old O
vs. O
â‰¥65 O
years O
old O
) O
, O
gender O
( O
male O
vs. O
female O
) O
, O
ECOG O
PS O
( O
0 O
vs. O
â‰¥1 O
) O
, O
primary O
tumor O
location O
( O
right O
vs. O
left O
) O
, O
RAS O
status O
( O
wild O
- O
type O
vs. O
mutant O
) O
, O
time O
from O
first O
- O
line O
chemotherapy O
start O
( O
â‰¥18 O
months O
vs. O
< O
18 O
months O
) O
, O
and O
time O
from O
prior O
bevacizumab O
( O
â‰¤1 O
month O
vs. O
> O
1 O
month O
or O
no O
prior O
bevacizumab O
) O
. O
ORR O
, O
DCR O
, O
and O
safety O
analyses O
between O
treatment O
groups O
were O
performed O
using O
Fisher O
's O
exact O
test O
. O
Follow O
- O
up O
time O
was O
defined O
as O
time O
from O
study O
treatment O
start O
until O
the O
last O
followup O
date O
for O
censored O
cases O
. O
Statistical O
analyses O
were O
performed O
using O
IBM O
SPSS O
statistics O
version O
22.0 O
( O
IBM O
Corp O
, O
Armonk O
, O
NY O
) O
, O
and O
two O
- O
sided O
p O
< O
0.05 O
was O
considered O
statistically O
significant O
. O
 
Sixty O
patients O
received O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
and O
66 O
patients O
received O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
. O
Patient O
demographics O
and O
baseline O
characteristics O
are O
shown O
in O
Table O
1 O
. O
All O
patients O
had O
previously O
received O
fluoropyrimidine O
, O
oxaliplatin O
, O
and O
irinotecan O
. O
Most O
of O
the O
patients O
in O
each O
group O
had O
a O
history O
of O
treatment O
with O
angiogenesis O
inhibitors O
, O
including O
bevacizumab O
, O
ramucirumab O
, O
or O
ziv O
- O
aflibercept O
. O
Approximately O
half O
of O
patients O
had O
RAS O
wild O
- O
type O
tumors O
, O
and O
no O
patient O
had O
MSI O
- O
high O
tumor O
. O
BRAF O
V600E O
mutation O
was O
detected O
in O
one O
patient O
( O
1.7 O
% O
) O
in O
the O
trifluridine/ B-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
group E-DESC
and O
in O
four O
patients O
( O
6.1 O
% O
) O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
. O
Patients O
with O
left O
- O
sided O
primary O
tumors O
were O
dominant O
in O
both O
groups O
and O
comprised O
81.7 O
% O
of O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
group E-DESC
and O
84.8 O
% O
of O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
. O
Median O
interval O
from O
study O
treatment O
start O
to O
first O
computed O
tomography O
evaluation O
was O
1.8 O
months O
in O
both O
groups O
. O
Median O
follow O
- O
up O
was O
7.1 O
months O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
groups E-DESC
and O
7.2 O
months O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
. O
After O
study O
treatment O
discontinuation O
, O
41.7 O
% O
of O
patients O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
groups E-DESC
and O
48.5 O
% O
of O
patients O
in O
the O
trifluridine/ B-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
received O
subsequent O
antitumor O
therapy O
including O
regorafenib O
( O
31.7 O
vs. O
39.4 O
% O
) O
, O
clinical O
trial O
therapy O
( O
6.7 O
vs. O
4.5 O
% O
) O
, O
and O
cytotoxic O
chemotherapy O
( O
3.3 O
vs. O
6.0 O
% O
) O
. O
 
Patients O
in O
the O
trifluridine O
/ O
tipiracil O
plus O
bevacizumab O
group O
had O
significantly O
longer O
PFS S-METRIC
compared O
with O
those O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
( B-RESULTS
HR I-RESULTS
0.69 I-RESULTS
; I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
0.48 I-RESULTS
- I-RESULTS
0.99 I-RESULTS
; I-RESULTS
log I-RESULTS
- I-RESULTS
rank I-RESULTS
p I-RESULTS
= I-RESULTS
0.037 I-RESULTS
) E-RESULTS
. O
Median B-METRIC
PFS E-METRIC
was O
3.7 B-RESULTS
months I-RESULTS
( I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
2.3 I-RESULTS
- I-RESULTS
5.1 I-RESULTS
months I-RESULTS
) E-RESULTS
in O
the O
trifluridine/ B-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
group O
and O
2.2 B-RESULTS
months I-RESULTS
( I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
1.8 I-RESULTS
- I-RESULTS
2.6 I-RESULTS
months I-RESULTS
) E-RESULTS
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
( O
Fig O
. O
1a O
) O
. O
PFS B-RESULTS
rate I-RESULTS
at I-RESULTS
16 I-RESULTS
weeks I-RESULTS
was I-RESULTS
46.6 I-RESULTS
and I-RESULTS
33.9 I-RESULTS
% I-RESULTS
, I-RESULTS
respectively I-RESULTS
. I-RESULTS
In I-RESULTS
multivariate I-RESULTS
analysis I-RESULTS
, I-RESULTS
similar I-RESULTS
PFS I-RESULTS
was I-RESULTS
observed I-RESULTS
between I-RESULTS
groups I-RESULTS
( I-RESULTS
adjusted I-RESULTS
HR I-RESULTS
0.62 I-RESULTS
; I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
0.42 I-RESULTS
- I-RESULTS
0.90 I-RESULTS
, I-RESULTS
p I-RESULTS
= I-RESULTS
0.01 I-RESULTS
) E-RESULTS
. O
Subgroup O
analyses O
also O
showed O
a O
PFS S-METRIC
benefit O
for O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
compared O
with O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
for O
all O
parameters O
except O
ECOG O
PS O
( O
Table O
2 O
) O
. O
 
Median O
OS O
was O
8.6 O
months O
( O
95 O
% O
CI O
6.9 O
- O
10.3 O
months O
) O
for O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
and O
8.0 O
months O
( O
95 O
% O
CI O
6.6 O
- O
9.4 O
months O
) O
for O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
( O
Fig O
. O
1b O
) O
. O
In O
multivariate O
analysis O
, O
an O
OS O
benefit O
was O
also O
observed O
for O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
compared O
with O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
, O
but O
without O
statistical O
significance O
( O
HR O
0.74 O
; O
95 O
% O
CI O
0.48 O
- O
1.14 O
; O
log O
- O
rank O
p O
= O
0.164 O
) O
. O
Similarly O
to O
PFS S-METRIC
, O
longer O
OS O
was O
observed O
for O
all O
subgroups O
, O
except O
ECOG O
PS O
. O
 
Three O
patients O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
group E-DESC
and O
one O
patient O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
had O
partial O
response O
, O
resulting O
in O
a O
5.0 O
and O
1.5 O
% O
ORR O
for O
each O
group O
, O
respectively O
( O
p O
= O
0.35 O
) O
. O
Disease O
control O
was O
achieved O
in O
32 O
patients O
( O
53.3 O
% O
) O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
group E-DESC
and O
in O
30 O
patients O
( O
45.5 O
% O
) O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
( O
p O
= O
0.48 O
) O
( O
Table O
3 O
) O
. O
Additionally O
, O
proportion O
of O
patients O
with O
6 O
months O
or O
longer O
of O
disease O
control O
were O
significantly O
higher O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
group E-DESC
than O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
( O
26.7 O
% O
vs. O
12.1 O
% O
, O
p O
= O
0.04 O
) O
. O
 
All O
patients O
initially O
received O
full O
- O
dose O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
and B-DESC
bevacizumab E-DESC
or O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
. O
Any O
cycle O
delay O
for O
â‰¥4 O
days O
was O
registered O
in O
37 O
( O
61.7 O
% O
) O
and O
27 O
( O
40.9 O
% O
) O
patients O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
group E-DESC
and O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
groups E-DESC
( O
p O
= O
0.02 O
) O
, O
and O
trifluridine O
/ O
tipiracil O
dose O
reductions O
were O
required O
in O
10 O
( O
16.7 O
% O
) O
and O
15 O
( O
22.7 O
% O
) O
patients O
( O
p O
= O
0.50 O
) O
, O
respectively O
. O
 
Adverse O
events O
are O
summarized O
in O
Table O
4 O
. O
Overall O
, O
grade O
â‰¥ O
3 O
adverse O
events O
were O
more O
frequent O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
than O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
( O
n O
= O
41 O
, O
68.3 O
% O
vs. O
n O
= O
36 O
, O
54.5 O
% O
; O
p O
= O
0.14 O
) O
. O
Incidence O
of O
grade O
â‰¥ O
3 O
neutropenia O
was O
slightly O
higher O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab I-DESC
group E-DESC
than O
in O
the O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy I-DESC
group E-DESC
, O
although O
this O
difference O
was O
not O
statistically O
significant O
( O
50.0 O
% O
vs. O
40.9 O
% O
; O
p O
= O
0.37 O
) O
. O
In O
 
In O
conclusion O
, O
in O
the O
present O
study O
trifluridine B-DESC
/ I-DESC
tipiracil E-DESC
plus B-DESC
bevacizumab E-DESC
was O
shown O
to O
have O
superior O
clinical O
activity O
compared O
with O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
in O
patients O
with O
heavily O
pretreated O
mCRC O
. O
Additionally O
, O
similarly O
to O
trifluridine B-DESC
/ I-DESC
tipiracil I-DESC
monotherapy E-DESC
, O
toxicities O
observed O
with O
the O
combination O
were O
manageable O
in O
the O
real O
- O
world O
setting O
. O
 